Cancer Peer Reviewed Journals

OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals. Each and every article undergoes a peer-review process to assess the quality of the article. Generally, these publications appreciate articles those that are accessible even to those people who are not specialist in the field but are interested in those research topic. These journals are periodical publications that are intended to share the progress of science. OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals. Despite the large economic and intellectual efforts, cancer is still not easily treatable disease by conventional therapies. This led ultimately to reconsider hyperthermia, like one of interesting treatment methods connected to immunity and tumor metabolism. Hyperthermia has also the ability to play an additional role when used together with the conventional methods of treatment: surgery, radiotherapy, chemotherapy and immunotherapy. Recent trials in Holland and Germany have demonstrated that hyperthermia can prolong life and decrease disease re-appraisal when used in combination with radiotherapy and chemotherapy. Some tumors seem more responsive than others. In this brief summary author was attempt to give a vision of hyperthermia from a physical stand point, but more importantly we will give clinical and biological aspects. The results obtained in these trials on certain types of cancers such as cervix cancer, recurrent breast cancer and head neck cancer, melanoma, sarcomas, liver, glioblastoma and pancreatic cancer support the use of this technique, although some clinical and technical problems persist and have not been completely resolved. Citation: Baronzio G, Parmar G, Ballerini M, Szasz A, Baronzio M, et al. (2014) A Brief Overview of Hyperthermia in Cancer Treatment. J Integr Oncol 3:115. doi: 10.4172/2329-6771.1000115

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on April, 2024